Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with a poor prognosis. We analyzed BCL-2 family member expression levels of 34 samp...

Full description

Bibliographic Details
Main Authors: Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, Isabel Ferreiro-Neira, Taylor Hoff, Zachary A Cooper, Rizwan Haq, David J Panka, Lawrence N Kwong, Michael A Davies, James C Cusack, Keith T Flaherty, David E Fisher, James W Mier, Jennifer A Wargo, Ryan J Sullivan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4077767?pdf=render

Internet

http://europepmc.org/articles/PMC4077767?pdf=render

Similar Items